{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:18:39Z","timestamp":1788542319080,"version":"build-2803163510"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective\/background:<\/jats:title>\n                    <jats:p>\n                      Tuberculosis (TB) is a worldwide public health problem. It is a contagious and grave disease caused by\n                      <jats:italic toggle=\"yes\">Mycobacterium tuberculosis<\/jats:italic>\n                      . Current drugs such as isoniazid, pyrazinamide, and rifampicin used for the treatment of tuberculosis are potentially hepatotoxic and can lead to drug hepatitis. In order to improve the follow-up of TB patients in Cameroon, we carried out a study which aimed to evaluate the hepatotoxicity risk factors associated with anti-TB drugs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The studies were performed on 75 participants who had visited the Loum District Hospital located in the littoral region of Cameroon for their routine consultation. Participants have been selected based on pre-established criteria of inclusion and exclusion. Prior to the informed consent signature, patients were given compelling information about the objective and the result output of the study. They were questioned about antioxidant food and alcohol consumption as well as some clinical signs of hepatotoxicity such as fever, nausea, vomiting, and tiredness. The collected blood was tested for the determination of biochemical markers (transaminases and C-reactive protein) using standard spectrophotometric methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Biochemical analysis of samples showed a significant increase (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; .05) of aspartate aminotransferase and alanine aminotransferase values in TB patients coinfected with human immunodeficiency virus\/AIDS (33.28\u00b116.58UI\/L and 30.84\u00b117.17UI\/L, respectively) compared with the respective values of the controls (16.35\u00b15.31UI\/L and 16.45\u00b14.83UI\/L). Taking individually, the liver injury patient percentage of TB patients was significant compared to TBC when considering alanine aminotransferase and aspartate aminotransferase parameters. When considering risk factors, antioxidant food consumption significantly reduced the liver injury patient percentage for the above parameters, whereas an opposite situation was observed with alcohol consumption between TB-coinfection and TB patients. Regarding the C-reactive protein results, the percentage of positive tests was very high among coinfected patients (40%) compared with the control (15%). The interactions between parameters related to alcohol consumption and intake of antioxidant foods showed a slight decrease in activity compared with interactions without food.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The results showed that human immunodeficiency virus status and alcohol consumption constitutes aggravating factors for the occurrence of hepatic toxicity. In addition, the consumption of antioxidant foods simultaneously with TB drugs help in reducing the hepatotoxic effects of these drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.ijmyco.2016.05.003","type":"journal-article","created":{"date-parts":[[2016,6,6]],"date-time":"2016-06-06T21:20:25Z","timestamp":1465248025000},"page":"482-488","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Risk assessment of hepatotoxicity among tuberculosis and human immunodeficiency virus\/AIDS-coinfected patients under tuberculosis treatment"],"prefix":"10.4103","volume":"5","author":[{"given":"Williams","family":"Ngouleun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prosper Cabral Biapa","family":"Nya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatole Constant","family":"Pieme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phelix Bruno","family":"Telefo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20260904","first-page":"78","article-title":"Incidence and risk factors for severe liver toxicity in HIV-infected patients on antituberculosis treatment","volume":"11","author":"Pukenyte","year":"2007","journal-title":"Int. J. Tuberc. Lung Dis"},{"key":"R5-17-20260904","first-page":"688","article-title":"Prevalence and risk factors of antituberculosis drug-induced hepatitis in Malaysia, Singapore","volume":"49","author":"Marzuki","year":"2008","journal-title":"Med. J"},{"key":"R6-17-20260904","first-page":"65","article-title":"The management of antituberculosis drug-induced hepatotoxicity","volume":"5","author":"Tahaoglu","year":"2001","journal-title":"Int. J. Tuberc. Lung Dis"},{"key":"R7-17-20260904","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4103\/TROG_20113203_167","article-title":"Antituberculous drug-induced liver injury: Current perspective","volume":"32","author":"Devarbhavi","year":"2011","journal-title":"Trop. Gastroenterol"},{"key":"R8-17-20260904","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1440-1843.2006.00941.x","article-title":"Antituberculosis drugs and hepatotoxicity","volume":"11","author":"Yew","year":"2006","journal-title":"Respirology"},{"key":"R9-17-20260904","doi-asserted-by":"crossref","first-page":"574","DOI":"10.4103\/1755-6783.109278","article-title":"Risk factors for antituberculosis drug-induced hepatotoxicity and its association with oxidative stress in North Indian population","volume":"5","author":"Ambreen","year":"2012","journal-title":"Ann. Trop. Med. Public Health"},{"key":"R10-17-20260904","first-page":"258","article-title":"Perfil bioquimco serico de provas funcionais hepatica e renal apos intoxicacao experimental com extratos aquosos de foltas de Melia azelarach L. em ratos albinos (Rattus norvegicus)","volume":"8","author":"Coimbra","year":"1995","journal-title":"Rev. Bras. Toxicol"},{"key":"R11-17-20260904","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3109\/01480549709003881","article-title":"Study of oxidative-stress in isoniazid-rifampicin induced hepatic injury in young rats","volume":"20","author":"Sodhi","year":"1997","journal-title":"Drug Chem. Toxicol"},{"key":"R14-17-20260904","first-page":"84","article-title":"Standard antituberculosis drug induced hepatotoxicity: Do the risk factors matter?","volume":"9","author":"Khoharo","year":"2010","journal-title":"JLUMHS"},{"key":"R15-17-20260904","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4038\/cmj.v51i1.1369","article-title":"Antituberculosis drug induced hepatitis\u2014A Sri Lankan experience","volume":"51","author":"Senaratne","year":"2006","journal-title":"Ceylon Med. J"},{"key":"R16-17-20260904","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s12072-008-9085-y","article-title":"A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases","volume":"2","author":"Makhlouf","year":"2008","journal-title":"Hepatol. Int"},{"key":"R17-17-20260904","first-page":"87","article-title":"A review of the evidence concerning hepatic glutathione depletion and susceptibility to hepatotoxicity after paracetamol overdose","volume":"3","author":"Kalsi","year":"2011","journal-title":"Emerging Med"},{"key":"R18-17-20260904","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/hep.1840210407","article-title":"Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid","volume":"21","author":"Durand","year":"1995","journal-title":"Hepatology"},{"key":"R19-17-20260904","first-page":"1104","article-title":"Adverse reactions of antituberculosis drugs in hospitalized patients: incidence, severity and risk factors, Pharmacoepidemiol","volume":"16","author":"Javadi","year":"2007","journal-title":"Drug Saf"},{"key":"R20-17-20260904","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.phrs.2004.10.009","article-title":"Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberculosis treatment","volume":"51","author":"Sharifzadeh","year":"2005","journal-title":"Pharmacol. Res"}],"container-title":["The International Journal of Mycobacteriology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S2212553116300322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S2212553116300322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/01929415-201605040-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:02:07Z","timestamp":1788541327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01929415-201605040-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1016\/j.ijmyco.2016.05.003","relation":{},"ISSN":["2212-5531","2212-554X"],"issn-type":[{"value":"2212-5531","type":"print"},{"value":"2212-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10]]}}}